Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations
A Pilot Study of a Rapid Access Platform for Investigational Drugs (RAPID) in Advanced Cancers
Sponsor: Mayo Clinic
A EARLY_PHASE1 clinical study on Advanced Malignant Neoplasm and Cervical Squamous Cell Carcinoma, this trial is completed. The trial is conducted by Mayo Clinic and has accumulated 9 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed EARLY_PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed EARLY_PHASE1
-
Jul 2019 — Jan 2021 [monthly]
Completed EARLY_PHASE1
Status: Active Not Recruiting → Completed
-
Jul 2018 — Jul 2019 [monthly]
Active Not Recruiting EARLY_PHASE1
Phase: PHASE2 → EARLY_PHASE1
▶ Show 4 earlier versions
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Oct 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Jan 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mayo Clinic
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .